Scientific deep-dive
GLP-1s and Antipsychotic Weight Gain: A Trial Cut Short
Semaglutide produced 13.88% weight loss against 0.42% on placebo in people taking clozapine, without altering clozapine levels or psychotic symptoms. The trial ended at 31 of an intended 80 because the drug ran out.
People with schizophrenia die 16 to 20 years earlier than the general population, mostly from cardiometabolic disease. Clozapine, the most effective antipsychotic there is for treatment-resistant illness, is associated with weight gain and metabolic dysfunction.[1] That is one of the sharpest trade-offs in medicine. A 2025 trial tested whether semaglutide could ease it, and got a striking answer from a very small number of people. A second Danish trial has since asked the same question at more than twice the size and in a broader group; it is covered in antipsychotics and metabolic harm.
What COaST found
COaST was an Australian randomized, placebo-controlled, blinded trial, run independently of pharmaceutical industry support, with its methods informed by people with lived experience. Adults aged 18 to 64 with schizophrenia or schizoaffective disorder, on clozapine for at least 18 weeks and with a BMI of 26 or more, were assigned to weekly semaglutide titrated to 2.0 mg or to placebo for 36 weeks.[1]
At 36 weeks the semaglutide group had lost 13.88% of body weight against 0.42% on placebo, a between-group difference of 13.46 percentage points (p below 0.0001).[1]
Why it ended at 31
The trial intended to recruit 80 participants. Recruitment began in August 2022 and was suspended in June 2024, not because of a safety problem or a lack of interest, but because the investigational product was unavailable.[1]
The shortage that emptied pharmacy shelves also stopped a trial in one of the most under-served populations in medicine, at 31 of an intended 80.
This register spends most of its time on the commercial side of GLP-1 supply: who is selling what, at what price, and whether it is what it claims to be. This is the same shortage, arriving somewhere else. When demand for a weight-loss drug outruns manufacturing, the research that would tell clinicians how to use it safely in the people who need it most is competing for the same vials.
The findings that mattered most were not about weight
For anyone taking clozapine, two questions come before weight loss, and COaST measured both.
- Clozapine levels did not change. There were no differences in clozapine or norclozapine concentrations between the groups.[1] Clozapine has a narrow therapeutic window and a serious monitoring burden, so a drug that shifted its levels would be a real problem.
- Psychotic symptoms did not change. No differences appeared in PANSS scores.[1] The worry that metabolic treatment might destabilize psychiatric illness was not borne out here.
- Tolerability was unremarkable. No serious adverse events were judged related to treatment, and rates of constipation were low.[1]
The wider literature points the same way on the safety question. A 2024 systematic review and meta-analysis of GLP-1 drugs in antipsychotic-induced weight gain (which could only pool exenatide and liraglutide, since nothing newer had enough data) found that neither adversely affected psychopathology.[2]
What the older drugs achieved
That same meta-analysis is a useful calibration, because it shows how much the newer drugs changed the picture. Across five randomized trials and one cohort study, liraglutide produced a mean weight loss of 4.70 kg and exenatide 2.48 kg, and the exenatide result did not reach statistical significance.[2] Other drugs that add weight, such as gabapentin and pregabalin, have no comparable GLP‑1 trial at all.
Against that, a 13.88% body-weight reduction is a different order of result. It is also from a much smaller sample, on a newer drug, and the comparison is across separate trials rather than a head-to-head. Our note on reading evidence across trials covers why that distinction matters.
Frequently Asked Questions
References
- 1.Siskind D, Baker A, Arnautovska U, et al. Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator-blinded, randomised controlled trial in Australia The Lancet Psychiatry. 2025. PMID: 40506208.
- 2.Bak M, Campforts B, Domen P, et al. Glucagon-like peptide agonists for weight management in antipsychotic-induced weight gain: A systematic review and meta-analysis Acta Psychiatrica Scandinavica. 2024. PMID: 39048532.
Compare the sellers
Related research
GLP-1s and Worsening Mental Illness
Semaglutide was associated with 42% lower risk of worsening mental illness in people with depression and anxiety. Exenatide and dulaglutide showed nothing. Four drugs, one class, two very different results.
5 min read
Antidepressants and a GLP-1: Ozempic, Wellbutrin, Lexapro and What the Labels Say
No GLP-1 label names an antidepressant as an interaction, and people on antidepressants lost as much weight on semaglutide as everyone else. The real overlaps: stacked nausea, slowed absorption of tablets, and two bupropion rules.
11 min read
Tirzepatide Versus Semaglutide on Mood
Across more than 85,000 matched pairs over two years, psychiatric outcomes were the same for both drugs. Against older GLP-1s, semaglutide was associated with about half the hazard of suicidal ideation.
5 min read
Semaglutide and Motivation
Semaglutide reduced how heavily people with depression discounted effort, while leaving their sensitivity to probability unchanged. That dissociation is what makes the finding hard to dismiss.
5 min read
When the Primary Endpoint Fails and a Secondary Doesn't
A randomized trial in 72 people with major depressive disorder found no effect on executive function, its primary outcome. A secondary cognition measure cleared p=0.03, and that is the one that will be reported.
5 min read
GLP-1 Drugs and Suicidal Thoughts: The Warning Came Off in 2026
In February 2026 the Suicidal Behavior and Ideation section was removed from the Wegovy, Zepbound and Saxenda labels, after three large studies looked for a signal and none found one.
7 min read
Where to get semaglutide online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
WellMedRx
Comparing compounded and brand GLP-1 plans with a published state list
From $49/mo
Get started →YourEra
From $99/mo
Get started →Collective
From $59/mo + membership
Get started →